{"id":"W4412654447","doi":"10.1080/10428194.2025.2532674","title":"Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVERSANA (Canada)","funders":"European Union Studies Association; Kite Pharma; Genmab; Genentech Foundation; Daiichi Sankyo Europe; Janssen Biotech; AbbVie Canada; Pharmacyclics; Seattle Genetics; Genentech; MorphoSys; Seagen; Incyte; TG Therapeutics; bluebird bio; Novartis Portugal; BeiGene; Merck KGaA; Regeneron Pharmaceuticals; Astellas Pharma; Takeda Pharmaceuticals U.S.A.; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Adverse effect; Oncology; Confidence interval; Odds ratio; Refractory (planetary science); Lymphoma; Cytokine release syndrome; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004213064,0.001288175,0.002331361,0.0005494784,0.0001890224,0.0009524571,0.0008580519,0.001045321,0.008635209],"category_scores_gemma":[0.006742716,0.0004212799,0.005569275,0.0004225697,0.0005555911,0.0007987702,0.0008979308,0.002105014,0.0006874137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008685937,"about_ca_system_score_gemma":0.0009050826,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001194277,"about_ca_topic_score_gemma":0.00198486,"domain_scores_codex":[0.9954294,0.003377332,0.000281443,0.000366782,0.000349556,0.0001954062],"domain_scores_gemma":[0.9975267,0.001195874,0.0007014865,0.0002263523,0.0001566456,0.0001929421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.944069,0.001179653,0.001811155,0.002206306,0.01927623,0.00003515503,0.000056894,0.001462327,0.001666458,0.000636785,0.0008888057,0.02671128],"study_design_scores_gemma":[0.7162392,0.187506,0.02395371,0.0005496057,0.04831421,0.0002005258,0.0001455864,0.006753692,0.003827109,0.003548736,0.008837657,0.0001239854],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9517245,0.02328562,0.005065877,0.000809963,0.001245167,0.003838344,0.004785182,0.0002208508,0.009024591],"genre_scores_gemma":[0.9906778,0.001738784,0.00235661,0.0005940357,0.0001600262,0.001375904,0.001331643,0.00001918133,0.001746107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008635209,"threshold_uncertainty_score":0.02888769,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.027151610728664,"score_gpt":0.2986257331563524,"score_spread":0.2714741224276884,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}